Donanemab delivers for Lilly
Pivotal data on the Alzheimer’s project beat expectations, raising hopes for a swift reimbursement U-turn.
Key second-quarter clinical readouts for pharma
Lilly’s Alzheimer's and obesity results, outcomes for Novo Nordisk and oncology data for Merck & Co and Astrazeneca.
World ADC 2023 – targeting the folate receptor rises from the ashes
Zymeworks, Profoundbio, Elucida and Immunogen itself piggyback on Elahere’s success to develop a better antibody-drug conjugate.
Morphic looks to justify “oral Entyvio” excitement
Big hopes have built behind Morphic’s MORF-057 in ulcerative colitis, and a key trial reads out imminently.
The world's twelfth VEGF drug will be sold by Takeda
The Japanese company keeps the licensing fires burning with a $400m deal for Hutchmed’s fruquintinib.
A year of two halves for US approvals
FDA green lights picked up in the second half, but for the really impressive number look at year-five sales.
Eisai learns from Biogen’s Aduhelm disaster
Leqembi's accelerated approval sees Eisai upholding its part of the bargain, setting a reasonable price and moving fast with confirmatory data.